Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date

Jayson I L Bastien, Katharine A. McNeill, Howard A. Fine

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

During the last decade, extensive multiplatform genome-wide analysis has yielded a wealth of knowledge regarding the genetic and molecular makeup of glioblastoma multiforme (GBM). These profiling studies support the emerging view that GBM comprises a group of highly heterogeneous tumor types, each with its own distinct molecular and genetic signatures. This heterogeneity complicates the process of defining reliable intertumor/intratumor biological states, which will ultimately be needed for classifying tumors and for designing effective customized therapies that target resultant disease pathways. The increased understanding of the molecular pathogenesis of GBM has brought the hope and expectation that such knowledge will lead to better and more rational therapies directed toward specific molecular targets. To date, however, these expectations have largely been unrealized. This review discusses some of the principal genetic and epigenetic aberrations found in GBM that appear promising for targeted therapies now and in the near future, and it offers suggestions for future directions concerning the rather disappointing results of clinical trials to date.

Original languageEnglish (US)
Pages (from-to)502-516
Number of pages15
JournalCancer
Volume121
Issue number4
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Glioblastoma
Molecular Biology
Therapeutics
Epigenomics
Neoplasms
Clinical Trials
Genome

Keywords

  • Clinical trials
  • Epigenetic
  • Genetic
  • Glioblastoma
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. / Bastien, Jayson I L; McNeill, Katharine A.; Fine, Howard A.

In: Cancer, Vol. 121, No. 4, 01.01.2015, p. 502-516.

Research output: Contribution to journalArticle

Bastien, Jayson I L ; McNeill, Katharine A. ; Fine, Howard A. / Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. In: Cancer. 2015 ; Vol. 121, No. 4. pp. 502-516.
@article{62d10a6a141742faa655fa694f580ec6,
title = "Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date",
abstract = "During the last decade, extensive multiplatform genome-wide analysis has yielded a wealth of knowledge regarding the genetic and molecular makeup of glioblastoma multiforme (GBM). These profiling studies support the emerging view that GBM comprises a group of highly heterogeneous tumor types, each with its own distinct molecular and genetic signatures. This heterogeneity complicates the process of defining reliable intertumor/intratumor biological states, which will ultimately be needed for classifying tumors and for designing effective customized therapies that target resultant disease pathways. The increased understanding of the molecular pathogenesis of GBM has brought the hope and expectation that such knowledge will lead to better and more rational therapies directed toward specific molecular targets. To date, however, these expectations have largely been unrealized. This review discusses some of the principal genetic and epigenetic aberrations found in GBM that appear promising for targeted therapies now and in the near future, and it offers suggestions for future directions concerning the rather disappointing results of clinical trials to date.",
keywords = "Clinical trials, Epigenetic, Genetic, Glioblastoma, Targeted therapy",
author = "Bastien, {Jayson I L} and McNeill, {Katharine A.} and Fine, {Howard A.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1002/cncr.28968",
language = "English (US)",
volume = "121",
pages = "502--516",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date

AU - Bastien, Jayson I L

AU - McNeill, Katharine A.

AU - Fine, Howard A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - During the last decade, extensive multiplatform genome-wide analysis has yielded a wealth of knowledge regarding the genetic and molecular makeup of glioblastoma multiforme (GBM). These profiling studies support the emerging view that GBM comprises a group of highly heterogeneous tumor types, each with its own distinct molecular and genetic signatures. This heterogeneity complicates the process of defining reliable intertumor/intratumor biological states, which will ultimately be needed for classifying tumors and for designing effective customized therapies that target resultant disease pathways. The increased understanding of the molecular pathogenesis of GBM has brought the hope and expectation that such knowledge will lead to better and more rational therapies directed toward specific molecular targets. To date, however, these expectations have largely been unrealized. This review discusses some of the principal genetic and epigenetic aberrations found in GBM that appear promising for targeted therapies now and in the near future, and it offers suggestions for future directions concerning the rather disappointing results of clinical trials to date.

AB - During the last decade, extensive multiplatform genome-wide analysis has yielded a wealth of knowledge regarding the genetic and molecular makeup of glioblastoma multiforme (GBM). These profiling studies support the emerging view that GBM comprises a group of highly heterogeneous tumor types, each with its own distinct molecular and genetic signatures. This heterogeneity complicates the process of defining reliable intertumor/intratumor biological states, which will ultimately be needed for classifying tumors and for designing effective customized therapies that target resultant disease pathways. The increased understanding of the molecular pathogenesis of GBM has brought the hope and expectation that such knowledge will lead to better and more rational therapies directed toward specific molecular targets. To date, however, these expectations have largely been unrealized. This review discusses some of the principal genetic and epigenetic aberrations found in GBM that appear promising for targeted therapies now and in the near future, and it offers suggestions for future directions concerning the rather disappointing results of clinical trials to date.

KW - Clinical trials

KW - Epigenetic

KW - Genetic

KW - Glioblastoma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84922496631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922496631&partnerID=8YFLogxK

U2 - 10.1002/cncr.28968

DO - 10.1002/cncr.28968

M3 - Article

C2 - 25250735

AN - SCOPUS:84922496631

VL - 121

SP - 502

EP - 516

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -